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Abstract
Purpose To characterize Health-Related Quality of Life (HRQoL) in ambulant individuals with RYR1-RM and to determine 
if a qualitative PRO tool (subjective self-assessment) complements PROMIS and Neuro-QoL scales to detect changes in 
HRQoL in ambulant individuals with RYR1-RM post N-acetylcysteine (NAC) treatment.
Methods The study used a mixed methods research (MMR) design applying methodological triangulation. Qualitative 
data were collected via semi-structured interviews using open-ended questions. Quantitative data were gathered through 
PROMIS and Neuro-QoL instruments. Additionally, qualitative data were transformed into quantitative data for subjective 
self-assessment and frequency analyses.
Results Qualitative results identified five domains and 33 subdomains as areas of interest. The most valuable were the impor-
tance of social impacts, the development of several coping strategies, both physical and psychological, and the identification 
of fatigue and weakness as key symptoms. Data transformation then categorized more than 3100 citations on frequency 
analyses, globally and by domain, visit, and participant. Regarding quantitative results, there was no clear evidence that any 
of the three PRO tools captured positive changes as a result of NAC treatment.
Conclusion Qualitative results showed a comprehensive characterization of HRQoL in this population based on a symptom/
patient-centered approach. These findings will inform future studies. Furthermore, given the similar findings across our 
multiple methods and endpoints, the introduction of MMR may be a valuable, complementary approach to clinical trials. 
MMR may be especially useful to incorporate in order to address and follow the FDA’s guidance and prioritization on the 
inclusion of affected individuals’ perspectives in clinical trials.
Keywords Neuromuscular disorders · Natural history study · Clinical trial · Health-Related Quality of Life · Mixed 
methods
Introduction
In the era of precision medicine, the importance of patient-
centered data is becoming increasingly recognized by 
regulators, clinicians, and the research community. Since 
the Food and Drug Administration’s (FDA’s) Guidance for 
Industry on Patient-Reported Outcome (PRO) Measures [1] 
and Patient-Focused Drug Development [2, 3], there has 
been a shift from traditional methods solely focused on clini-
cal study goals to the incorporation of participant experience 
outcomes. Research methods are now including the patient 
perspective early in order to ensure (and validate) that any 
changes measured are meaningful to those patients [4]. 
PROs can provide important insights into disease symptoms 
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or treatment side effects (e.g., pain, fatigue, or anxiety); 
functional outcomes (e.g., physical, social, emotional, etc.); 
and/or multidimensional assessment of the impact of both 
disease and treatment on physical, psychological, and social 
well-being, also known as Quality of Life (QoL) [5].
PROs can be used to generate both quantitative (e.g., 
questionnaires) and qualitative (e.g., interview, journals) 
data. Mixed methods research (MMR) employs quantita-
tive and qualitative approaches to provide a more compre-
hensive understanding of findings. MMR has been proposed 
as a best practice to inform Patient-Centered Outcomes 
Measures in rare diseases where quantitative methods alone 
have found challenges [6]. Thus, MMR was employed dur-
ing a combined natural history study and clinical trial of 
N-acetylcysteine (NAC) in Ryanodine 1-Related Myopathies 
(RYR1-RM) to facilitate an understanding of participants’ 
characterization of their condition and to identify any sub-
jective improvements post-intervention. RYR1-RM comprise 
the most common of the non-dystrophic neuromuscular dis-
orders with a pediatric incidence of > 1:90,000 in the United 
States, yet there are no FDA-approved treatments [7, 8].
Materials and methods
Standard protocol approvals, registrations, 
and patient consents
The RYR1 NAC clinical trial consisted of two components; 
a prospective natural history assessment and a parallel-
group, randomized, double-blind, placebo-controlled trial. 
The study was conducted at the National Institutes of Health 
(NIH) Clinical Center, Bethesda, MD, USA between 2015 
and 2017. The clinical trial is registered in the U.S. National 
Library of Medicine (NCT02362425). All procedures were 
approved by the NIH Combined Neuroscience Institutional 
Review Board (CNS IRB), and an Independent Monitoring 
Committee was established to oversee trial safety. All par-
ticipants and parents of participants < 18 years of age pro-
vided written informed consent, according to the Declaration 
of Helsinki, before enrollment. Assent was also obtained for 
those < 18 years of age. Participants attended three study 
visits at the NIH: baseline (0 months), pre-intervention 
(6 months), and post-intervention (12 months). Participants 
also completed a follow-up phone call (18 months). Rand-
omization was performed at the end of the second visit. For 
more information regarding the clinical trial, see the follow-
ing publication [9].
Study design and procedures
Common RYR1-RM clinical manifestations include delayed 
motor milestones, hypotonia, scoliosis, ophthalmoplegia, 
respiratory insufficiency, myalgia and rhabdomyolysis, exer-
tional heat stroke/myalgia, proximal/axial muscle weakness, 
and fatigue [10, 11]. Affected individuals reported fatigue as 
one of the more pervasive symptoms [12]. NAC was shown 
to improve measures of physical endurance and force pro-
duction in a preclinical setting [13, 14]. Therefore, we per-
formed a comparison of quantitative and qualitative PRO 
data to identify subjective improvements from NAC treat-
ment (PharmaNAC®, BioAdvantex Pharma Inc., Toronto, 
Ontario, Canada). We used the National Institute of Nursing 
Research (NINR) Symptom Science Model [15] to guide 
the investigation of how patient-reported symptoms affect 
Health-Related Quality of Life (HRQoL) in RYR1-RM.
Our mixed method design uses methodological triangula-
tion. In this design the qualitative and quantitative compo-
nents are typically undertaken simultaneously and weighted 
equally, seeking convergence of findings to enhance the 
interpretability of a single phenomenon [16, 17]. Methodo-
logical triangulation is used to provide a complementary 
view from qualitative and quantitative approaches, balancing 
the strengths and weaknesses of both.
Qualitative data were collected via semi-structured inter-
views at each visit to characterize natural history of HRQoL 
in ambulant individuals with RYR1-RM prior to randomiza-
tion and to analyze drug effects post-intervention. Thus, indi-
vidual and collective viewpoints were addressed. The use 
of this design has been previously implemented in HRQoL 
and Neuromuscular Disorders (NMD) [18–20] research. 
One hundred-seven semi-structured interviews were con-
ducted using open-ended questions (Table 1) (i.e., forty-six 
from baseline visit, thirty-four from pre-intervention, and 
twenty-seven from post-intervention). Semi-structured inter-
views were recorded and transcribed verbatim to conduct 
thematic analysis [19, 20] through a multiphase approach, 
open-coding and axial-coding [21]. As RYR1-RM are slowly 
progressive diseases, this was considered when analyzing 
HRQoL and treatment effects. Three researchers conducted 
qualitative analysis. All researchers codified an initial set of 
five semi-structured interviews to identify common areas 
of interest (domains/subdomains) and to assess agreement. 
Once agreement was confirmed, the remaining interviews 
were distributed among the researchers for analysis. A bal-
anced number of interviews were provided to each researcher 
considering the following variables: males/females, adults/
children, and pre-intervention/post-intervention. Three addi-
tional meetings were conducted to discuss the inclusion of 
new domains/subdomains until saturation was achieved [22]. 
Differences in coding were resolved through consensus and 
tighter definitions of subdomains [23]. Likewise, interpre-
tation and selection of quotes for publication was also dis-
cussed to ensure agreement among researchers.
We transformed qualitative data into quantitative results, 
a standard procedure in mixed methods research, counting 
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the number of times with which each domain/subdomain 
was mentioned in semi-structured interviews [19, 24, 25]. 
The average and percentage of citations was also calculated 
for each domain/subdomain. This procedure was performed 
globally (i.e., considering all data), by domain (i.e., analyz-
ing every identified domain separately), by visit (i.e., consid-
ering the records for each visit independently), and by par-
ticipant (i.e., evaluating data provided for each participant 
individually). When necessary, the percentage score was 
normalized to compare domains/subdomains. Additionally, 
a word frequency analysis was also completed. Results from 
that analysis were presented through a word cloud image 
[26]. Qualitative data were also used to evaluate treatment 
effects via subjective self-assessment. Because we were 
evaluating treatment-related improvements in this analy-
sis, a binary score was assigned to participants based on 
their comments on post-intervention interviews (i.e., “posi-
tive effect” [+ 1] vs “no change” [0]). Disease progression 
was assessed during qualitative analysis, where only minor 
side effects were reported. Subjective self-assessment was 
provided by participants under 18 years of age and/or their 
parents, when necessary. Counts of positive and no change 
reports were compared between the two treatment groups 
(NAC vs. placebo) via Fisher’s exact test.
Finally, the Patient-Reported Outcomes Measurement 
Information System (PROMIS) [27] and Quality of Life in 
Neurological Disorders (Neuro-QoL) [28] scores were gath-
ered. Twenty domains from PROMIS and Neuro-QoL were 
analyzed separately via t-test (i.e., anger, anxiety, depres-
sion, fatigue, mobility, pain, peer relations, social, and upper 
extremity for PROMIS; and anger, anxiety, applied cogni-
tion, depression, fatigue, mobility, pain, participate in SRA, 
social relations, stigma, and upper extremity for Neuro-QoL, 
respectively). For PROMIS and Neuro-QoL, the change 
in T-score between pre- and post-treatment was analyzed. 
T-score distributions rescale raw scores into standardized 
scores with a mean of 50 and a standard deviation (SD) of 
10. More specifically, the change in T-score between Month 
12 and Month 6 was calculated (Month 12 minus Month 
6). Month 0 was used instead of Month 6 whenever Month 
6 was missing. In some cases, the participant had both a 
self-report and a parent proxy PROMIS or Neuro-QoL 
T-score on the same domain. Also, Case 33 had two differ-
ent PROMIS or Neuro-QoL T-scores on the same domain. 
In these cases, and within each specific domain, the aver-
age change was calculated and analyzed. To compare the 
treatment groups (NAC and placebo), a t-test on the T-score 
change was performed.
SAS version 9.4 software (SAS Institute Inc., Cary, NC) 
was used to conduct all statistical analysis and Nvivo ver-
sion 12.3 software was used to perform qualitative and data 
transformation analyses.
Study goals
The primary goal of this study was to characterize HRQoL 
in ambulant individuals with RYR1-RM to support future 
research. Questionnaire data (i.e., T-scores generated by 
PROMIS and Neuro-QoL instruments) have shown limita-
tions assessing rare diseases [6]. As a secondary goal, this 
study thus aimed to determine if open-ended data (gathered 
via subjective self-assessment interviews) captured addi-
tional information to detect changes to HRQoL in ambulant 
individuals with RYR1-RM post-NAC treatment.
Research questions and hypothesis
Q1  What are the major concerns/issues regarding HRQoL 
in ambulant individuals affected with RYR1-RM?
Q2  How do ambulant individuals with RYR1-RM describe 
the major concerns/issues affecting their HRQoL?
Table 1  Open-ended questions 
from semi-structured interviews Questions for all interviews
 What are the symptoms of RYR1 related myopathy that give you the most trouble?
 If there was one thing you would like a treatment to address, what would it be?
 How much of the time is fatigue a problem?
 Can you describe your fatigue?
 What do you do to make the fatigue less of a problem?
 What is your experience with others’ perspective of your symptoms?
 How do you relate to others around your symptoms? Social, education, financial?
 Is there anything else you would like to tell me about your quality of life?
 How would you rate your quality of life?
Additional questions for post-intervention interviews
 Did you observe that NAC or placebo alleviated any of the symptoms you mentioned that give you the 
most trouble? If so, could you elaborate on which symptoms?
 How did the treatment affect fatigue specifically?
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Our research hypothesis was that subjective self-assess-
ment will capture additional information and complement 
PROMIS and Neuro-QoL instruments to detect changes in 
HRQoL in ambulant individuals with RYR1-RM when com-
paring the NAC and placebo groups.
Participants
One hundred-fifty individuals were screened for participa-
tion in this study, of which 53 were eligible and enrolled 
(Fig. 1). Of these, 47 participants completed at least one 
interview in which we were able to perform qualitative 
analysis. Only participants with complete data from all 
three tools (subjective self-assessment, PROMIS, and 
Neuro-QoL) were included in quantitative analysis to avoid 
potential confounding factors of varying data from differ-
ent participants. Therefore, quantitative analysis included 
26 participants—13 in each of NAC and placebo groups. 




Five domains and 33 subdomains were identified as areas 
of interest in participants with RYR1-RM regarding their 
HRQoL. Quality of life domain comprised 11 subdomains 
(i.e., anxiety, career/financial impact, diagnostic journey, 
disease progression, frustration, general assessment, posi-
tive aspects, sadness, self-care/home maintenance, self-
esteem, and social impacts); adaptive strategy contained 
six subdomains (i.e., accommodation, equipment, help from 
others, physical behaviors, physical therapy, and psycho-
logical strategy); symptoms covered 12 subdomains (i.e., 
Fig. 1  Consort diagram of study flow
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compounding illness-conditions, fatigue, fine motor, heat 
intolerance, mobility, muscle spasms, numbness, pain, 
respiratory difficulties, rhabdomyolysis, scoliosis, and 
weakness); future thoughts comprised two subdomains 
(i.e., fears and treatment desires); and post-intervention 
included two subdomains (i.e., treatment benefits and side 
effects). The most representative domains/subdomains, by 
their importance and depth are provided in Table 3 to reveal 
participants’ experiences/opinions. In this table, research-
ers’ interpretations of participants’ interviews are labeled 
with domain and subdomain. Transcripts of participants’ 
comments are also included. A reference code noting de-
identified case number, visit, researcher initials, and Nvivo 
transcript reference number follows each quote.
Data transformation
More than 3100 citations were categorized. The results of 
the global analysis and analysis by domain are displayed in 
Fig. 2. Examples of results for analyses by visit and partici-
pant are available as Supplemental Data (Tables e-1 to e-3 
and Fig. e-1).
Results from the word frequency analysis were summa-
rized as a word cloud (Fig. 3).
Post-intervention comments transformed into a binary 
value (positive effect or no change) revealed a higher fre-
quency of subjective positive changes observed in the NAC 
group versus the placebo group (69% versus 38%) and a 
higher frequency of subjective no change observed in the 
placebo group versus the NAC group (62% versus 31%), but 
the p value from Fisher’s exact test (two-sided) was 0.24.
Quantitative analysis
Only three domains from the Neuro-QoL instrument, anxi-
ety, stigma, and fatigue, showed some evidence of improve-
ment in T-scores in the NAC group compared to placebo. 
The p values for these domains ranged between 0.014 and 
0.034, whereas all other p values for the Neuro-QoL and 
PROMIS were above 0.05 (Table 4). These p values were 
not corrected for multiple analyses.
Discussion
Based on our qualitative results, we were able to identify 
and characterize major HRQoL concerns/issues in ambu-
lant individuals affected with RYR1-RM. The Quality of 
life domain was the most relevant for participants when 
discussing their HRQoL. The most emphasized subdomain 
was social impacts, depicting specific perceptions, limita-
tions, and deficits of understanding due to the disease. For 
example, mildly-affected participants were widely accused 
of being “lazy” or “liars”, which is consistent with previous 
Table 2  Participant demographic information
Variables Overall participants Qualitative analysis Quantitative analysis NAC group Placebo group
N 53 47 26 13 13
Cohort % 100% 89% 50% 25% 25%
Gender
 Female 29 (55%) 27 (57%) 15 (58%) 8 (62%) 7 (54%)
 Male 24 (45%) 20 (43%) 11 (42%) 5 (38%) 6 (46%)
Age
 Total 29.8 ± 17.6 29.6 ± 17.1 28.3 ± 17.2 32.8 ± 16.3 23.8 ± 17.6





















 White 47 (89%) 42 (89%) 25 (96%) 12 (92%) 13 (100%)
 Black 6 (11%) 5 (11%) 1 (4%) 1 (8%) 0 (0%)
Location
 Northeast 10 (19%) 10 (21%) 4 (15%) 1 (8%) 3 (23%)
 Southeast 9 (17%) 9 (19%) 7 (27%) 5 (39%) 2 (15%)
 Midwest 10 (19%) 5 (11%) 2 (8%) 2 (15%) 0 (0%)
 Southwest 4 (7%) 4 (9%) 3 (12%) 2 (15%) 1 (8%)
 West 10 (19%) 10 (21%) 4 (15%) 2 (15%) 2 (15%)
 Abroad 10 (19%) 9 (19%) 6 (23%) 1 (8%) 5 (39%)
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Table 3  Transcripts from the most representative domains/subdomains
Quality of life > Social impacts: the most remarkable issue reported in interviews was a lack of other people’s understanding of RYR1 myopa-
thies. Our first thought was to attribute this to the fact that RYR1-RM is rare and thus not understood by the general population. However, the 
interviewees’ comments focused primarily on their lack of apparent symptoms. As other people are not able to easily recognize a myopathy at 
first glance in milder cases, they tend to minimize the physical effects of the disease. This observation highlighted the conundrum of displaying 
visual symptoms. For this reason, participants struggled to explain their condition, typically choosing one of these options: giving very little 
information or saying nothing at all, using the name of a similar disease that is widely known such as Amyotrophic Lateral Sclerosis (ALS), or 
stating they have a “muscle condition” and describing its main symptoms (e.g., fatigue, pain, weakness, etc.). In addition, participants indicated 
similar situations happened on a daily basis, increasing the effect of this social issue. This subdomain revealed direct connections with several 
other domains such as symptoms, adaptive strategy, and future thoughts.
“when I’m standing up, generally I think it doesn’t, people don’t perceive that there’s a challenge that I have. When I have things like, I had it 
with the shuttle from the airport where I had to ask the gentleman to put down the wheelchair lift, and he kinda looked at me like ‘Well, you 
don’t look like anything’s wrong’, that sort of thing. Having to explain that I have a form of, I have muscular dystrophy, and I simply can’t do 
stairs or it’s too difficult for me to do, is generally how I explain it. Whether or not it’s believable… I think some folks don’t quite understand it. 
If something doesn’t look wrong, it can’t be wrong” < C04VA_MMC > Ref.  [1]
Adaptive strategy > Physical behaviors: the most common solution mentioned for the main symptoms (e.g., fatigue, weakness, pain) was simply 
to cease activity and rest. This solution not only displayed a motor limitation, but also required increased organizational skills, as affected 
individuals needed more time to complete activities. Participants had to consider which activities were to take precedence, because they were 
not able to partake in all physical activities in which they would have liked to participate. Although these situations varied according to level of 
exertion, they reported a continuous and high degree of fatigue. This showed clear links between fatigue, psychological strategy, career/finan-
cial impact, and social impact subdomains.
“when I can’t go anymore, I just stop, basically. And then I usually don’t try to do any more that day, and just work on it another day a little 
bit… It will help some, but if I like, get to feeling a little better and then I start back, it will get worse. But it kind of depends on to what level of 
fatigue I get” (NAC) < C17VC_MMC > Ref. [1]
Adaptive strategy > Psychological strategy: whereas the previous paragraph explained how individuals with RYR1-RM faced effects of the 
disease from a functional approach, participants also used a psychological approach. The most common strategies included increased organiza-
tion, learning from previous experiences, and applying problem solving to each situation. These strategies required a constant focus on how to 
improve their QoL, which actually reduced QoL. This created additional psychological fatigue that compounded the physical fatigue they expe-
rienced. There was also a tendency to compare themselves with healthy individuals, bringing attention to the problems they faced and feelings 
of frustration with limitations. This subdomain had connections with psychological factors, such as fears, anxiety, frustration, and self-esteem, 
as well as physical aspects, such as fatigue, weakness, pain, or physical behaviors.
“It makes any situation that much more complicated, ‘cause I have to take into account will I be able to do it? Will there be an obstacle? I think 
I plan ahead a lot more. I think like almost a military strategist in terms of what will happen in this event? Will there be stairs? Will I have to 
sit on the floor? If I have to do that, how will I handle that? It’s a lot more of that. It’s just draining in a way to constantly have to, as opposed 
I think people who don’t aren’t affected by things like this and can flow through life without having to worry about those things” < C36VA_
ICC > Ref. [5]
Symptoms > Fatigue: participants reported their symptoms affected them on a daily basis, revealing the frequency of the disease’s impact. 
Indeed, most said these symptoms, not only fatigue but also weakness and pain, had a continuous influence in their lives, revealing the difficul-
ties associated with their physical condition. For this reason, they limited and organized their daily activities, drastically reducing their ability 
to perform motor tasks. In addition, participants described their fatigue, using words such as “depletion”, “exhausted”, “empty”, “drained”, 
“having zero left in the tank”, which points to the benefit of potentially improving fatigue. As in previous cases, the concept of fatigue spread 
to other subdomains such as physical behavior, self-care/home maintenance, career/financial impact, and mobility.
“Probably daily. I don’t really wake up feeling rested usually, and then I can usually do my daily morning stuff. I go to work. All that stuff, and 
then in the afternoon, typically, kind of when I’m winding down in the evenings. Sometimes, I’ll need to take a nap before I do things around 
the house for kind of, like, round two at the house… It’s just kind of like a general overall sleepiness. So, it’s not like, I don’t experience par-
ticular muscle fatigue in, like, a muscle group. It’s just, if I do everything I need to do for the day, I’ll come home, and I’ll be tired so, I’ll need 
to rest. It’s not necessarily a muscular tired. It’s more all over general fatigue” < C09VA_MMC > Ref. [3]
Future thoughts > Treatment desires: in general, participants expressed the symptoms they wanted most to be addressed by a potential treatment 
were fatigue and weakness. Having impairments in these areas limited physical performance considerably. Despite this, participants focused 
more on what they could do or what they could improve instead of dwelling on limitations. Similarly, they were committed to helping others 
rather than solely considering their own benefit. This revealed both a positive approach and a sense of social belonging related to the disease. 
All this information connected to several domains/subdomains in our research: quality of life, fatigue, social impact, positive aspects, and 
disease progression, strengthening the importance of the identified areas of analysis.
“I don’t know if this would be the same thing or not, but I would say energy or zero fatigue… I am hopeful about this trial. And, while I don’t 
know that it will provide a huge quality of life improvement for me, down the road if this and other trials help my children to have a much 
easier life, and I think that’s why Brandon is participating… That I think those are all good things. And so, recently I went with my son to, he 
has a different neurologist than I do, and he was very hopeful about if not treatments, at least ways that we can manage muscular dystrophy 
going forward. It’s not quite the hopeless condition that it once was” < C19VB_CCP > Ref. [1–2]
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reports in qualitative research on NMD [29, 30]. This finding 
highlights the importance of establishing positive interac-
tions to enhance HRQoL. General assessment and positive 
aspects also stood out as notable subdomains. Participants 
were very optimistic in their appraisals of their QoL as a 
result of internal acceptance, focus on improvement, encour-
aging experiences, and support of family and friends. This 
depicts a high level of resilience in facing their condition, 
which is a well-documented response to adversity in physi-
cal and mental health [31, 32]. The remaining subdomains, 
however, received moderate-to-little attention, highlighting 
that, globally, they were less important to participants than 
the previous subdomains. For example, negative experiences 
were linked to specific economic-work situations, unhappy 
moments, the progression of the disorder, daily care and 
domestic activities, annoyance reactions, difficulties in being 
diagnosed, and uneasy feelings. Most of these have been 
described in RYR1-RM [12, 33, 34] and other NMD [35, 36]. 
However, it is surprising that self-esteem was not explored 
in depth in participant interviews. This indicates very lit-
tle effect on self-esteem, which is in contrast to previous 
research in individuals with NMD [37, 38]. It is also worth 
noting that contrary results regarding anxiety have been 
reported in the RYR1-RM population [12]. All subdomains 
for quality of life revealed connections with the other identi-
fied areas of interest, especially with adaptive strategy and 
symptoms. This observation is based on the close interaction 
between QoL and HRQoL concepts [39].
The second domain was adaptive strategy, which gave 
insight into several coping strategies employed by partici-
pants. Most of these fell into the subdomains of physical 
behaviors and psychological strategy, which described the 
approaches taken to address motor restrictions (e.g., limiting 
physical activities, increasing rest periods, using external 
support, etc.) and psychological implications (e.g., planning 
ahead, scheduling energy, remaining positive, etc.). Implica-
tions in both areas were also reported recently for individu-
als with RYR1-RM [12] and HRQoL research in NMD [24]. 
Accommodation, equipment and help from others attained 
similar emphasis, disclosing the need for additional assis-
tance from institutions, tools, and people, respectively. These 
factors revealed a lack of independence for participants with 
RYR1-RM, which is a key aspect for the NMD population 
in general [20]. Surprisingly, physical therapy was scarcely 
mentioned by participants, with minor mentions of thera-
peutic and occupational interventions like horseback riding. 
For post-intervention interviews, drug assignment precedes the reference code. Pseudonyms were used to protect patient identity
Table 3  (continued)
Post-intervention > Treatment benefits: several participants reported positive results of using NAC for treatment in RYR1-RM. The most valu-
able benefits were related to reducing fatigue and increasing strength. Additionally, several patients also experienced reduced pain, which could 
be indirectly produced by a reduction of tiredness and/or an increase of strength. These observations revealed some gain in their motor per-
formance that in turn implied improvement in independence because they required less support in physical activities. Thus, some participants 
expressed access to a new and larger range of activities as well as a greater availability of time, suggesting that NAC impact was not limited 
to the physical domain. As expected, the strongest relationship for this subdomain was linked to the domain of symptoms, however, additional 
connections with other subdomains, such as physical behaviors, general assessment, or disease progression, were also present.
“It lessened it, I think. I don’t think I’m near as tired… I still can’t go up a flight of stairs without a handrail. But maybe it’s not quite as hard… 
I think there’s been little things that at the end of the day have equaled up to me not being as tired and as fatigued as I was because the com-
pletely washed out, complete drained, just can’t go no more” (NAC) < C32VC_CCP > Ref. [1]
“the weakness seems to be somewhat better. But it still exists, but it seems noticeably… I noticed it more in the first couple months, and then it 
seemed like it kind of hit a plateau and stayed at the same level throughout until the end… Like, yesterday, and since I’ve been on the medicine, 
I do notice that my recovery has been quicker than normal” (NAC) < C17VC_MMC > Ref. [1–3]
“They ruled my day from the moment I woke up in the morning. I woke up in pain every single morning. It was really significant. I wasn’t 
aware of how severe my pain was even though I had – even knowing I was in pain, I couldn’t really assess how severe it was until it was gone, 
because I had it my whole life. I was born with that level pain. I never had relief until six months ago. And it was breathtaking how dramatic it 
was not to have muscle pain, especially not to have ankle pain, to be able to wake up and then get up out of bed immediately instead of waking 
up and waiting up to two hours before I could get out of bed, because of the pain… And now I just, I go through the whole day. I don’t even 
really have to think about it… But then to have to lie there staring at the ceiling and thinking about things and imagining what I would do and 
having to deal emotionally that frustration of wanting to get up and live and take care of my children and work” (NAC) < C38VC_CCP > Ref. 
[1]
Post-intervention > Side effects: participants reported very few side effects regarding RYR1-RM treatment with NAC. Side effects that were 
reported were minor (e.g., acid reflux or headaches). In one case, a participant reported potential increased fatigue, but later contradicted that 
report. This supported the minimal risk involved on this research. Due to the specificity of this subdomain there were no links to other areas of 
the study.
“I had extreme fatigue and I don’t know if it’s just because it was the weather change or if it was the drug or what, and then I’ve had a shift 
where I’ve had less fatigue… I do see some improvements. Like, I was able to go up the stairs yesterday for the PT trial without holding on the 
railing, which I have never been able to do” (NAC) < C01VC_CCP > Ref. [1]
“From the medicine I had? Headaches” (placebo) < C24VC_ICC > Ref. [1]
“Some acid reflux” (placebo) < C34VC_MMC > Ref. [1]
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We posit this is due to the relative normality of this type of 
therapy in this population. However, this could be also due 
to differences in access to physical therapy services. This 
issue should be explored in depth in future research. Every 
adaptive strategy was linked to the specific symptoms of 
each participant, indicating the strong relationship between 
both domains, as might be expected.
Another important domain was symptoms. The most 
influential subdomain was fatigue, followed by weak-
ness. This is consistent with documented clinical effects 
of RYR1-RM [8, 11, 12, 33, 40–44]. Pain and impaired 
mobility were secondarily important in this study and 
were mainly described as consequences of fatigue and 
weakness. Likewise, there are several antecedents of pain 
Fig. 2  Data transformation results for global and domain analyses 
(N = 107). Total count (whole bar), average (A), global percentage for 
each domain (G), and domain percentage for each subdomain (D) are 
displayed. The percentages were normalized for the number of sub-
domains in each domain and given that post-intervention comments 
were only recorded on post-intervention interviews
1649Quality of Life Research (2020) 29:1641–1653 
1 3
and impaired mobility in affected individuals with RYR1-
RM [8, 10, 12, 34, 43]. The remaining subdomains were 
less widely reported and included issues more specific to 
individuals such as additional complications, malignant 
hyperthermia experiences, respiratory issues, hand dexter-
ity problems, and abnormal curvatures of the spine, align-
ing with manifestations of RYR1-RM [8, 11, 12, 33, 40, 
42, 44–46]. Rhabdomyolysis was not described in depth. 
However, it is possible that participants reported rhabdo-
myolysis involvement within the weakness subdomain, as 
previous research notes the importance of this symptom 
for individuals with RYR1-RM [10, 45, 46]. Finally, mus-
cle spasms and numbness were touched on but not elabo-
rated, suggesting they are not paramount. Despite this, 
these symptoms have been previously reported [43, 46]. 
Every aspect of the symptoms domain displayed a high 
influence on other subdomains, reinforcing the whole con-
struct and emphasizing the use of the Symptom Science 
Model [15].
The domain future thoughts captured feelings about 
events to come. The Fears subdomain contained concerns 
about potential issues, including limitations on activities, 
worsening symptoms, or genetic implications for children. 
Treatment desires, a subdomain consistent with recent quali-
tative data in NMD [35], was essentially focused on improv-
ing HRQoL as a result of increasing physical performance. 
These findings could be interpreted as a dualistic display 
(i.e., positive vs negative) of treatment expectations [47]. 
This domain was closely related to other identified domains/
subdomains such as symptoms and disease progression, bol-
stering their identification as areas of interest.
Finally, the post-intervention domain captured individ-
ual impressions of treatment effect after the NAC/placebo 
intervention, addressing our research hypothesis regarding 
whether or not these data captured additional information 
complementing PROMIS and Neuro-QoL instruments to 
detect changes in HRQoL in ambulant individuals with 
RYR1-RM post-treatment. These reactions were categorized 
as positive or no change. Participants’ feedback revealed 
valuable treatment benefits, most of which were related to 
increased levels of energy and strength, which are consistent 
with preclinical effects of NAC on ryr1 mutant zebrafish 
and mice [13, 14]. However, results from our quantitative 
analysis of Neuro-QoL and PROMIS T-scores were incon-
clusive. Social and psychological profits were also reported 
[39]. Only minor side effects were noted, providing further 
evidence that NAC is safe and well tolerated in this popula-
tion. As in previous subdomains, both options were directly 
connected to the specific symptoms of each participant, 
which indicates a straightforward relationship between both 
domains.
Regarding data transformation, analysis by domain 
exposed a clear imbalance in future thoughts and post-
intervention domains, recording more quotes for treatment 
desires and treatment benefits subdomains. This highlighted 
that participants with RYR1-RM tended to show more posi-
tive attitudes towards their HRQoL in comparison to their 
family, caregivers, or external observers, which is known as 
the “disability paradox” [48]. The “disability paradox” has 
been noted in previous research on NMD [49, 50]. Qual-
ity of life, adaptive strategy, and symptoms domains were 
relatively balanced. However, social impacts, psychological 
strategy, and fatigue subdomains scored higher number of 
comments for each case. These findings are consistent with 
the qualitative data, reinforcing the results obtained via both 
approaches.
The word cloud revealed the presence of three main 
groups of terms “people, family, friends, school, person, oth-
ers”; “fatigue, energy, weakness, myopathy, affected, symp-
toms”; and “quality, little, problem, better, harder, difficult, 
without, describe”. Those words reemphasize the impor-
tance of several domains/subdomains such as social impacts; 
symptoms and physical behaviors; and quality of life and 
adaptive strategy, respectively. These results also coincide 
with our previous findings from qualitative analysis.
Global analysis, involving transformed data, found bal-
anced percentages of all identified domains, considering 
the number of subdomains in each case and that post-
intervention comments were only reported on post-inter-
vention interviews. This outcome differed slightly from 
qualitative data, where quality of life, adaptive strategy 
and symptoms were more relevant, and suggested a similar 
Fig. 3  Word cloud summarizing word frequency analysis. Larger font 
sizes indicate a higher frequency of mentions; smaller font sizes a 
lower frequency
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influence of all five domains in HRQoL for participants 
with RYR1-RM. This slight difference highlights the value 
of the mixed methods approach because it allows for a 
more nuanced understanding of the data. Future thoughts 
and symptoms recorded lower percentage of comments 
than the remaining domains, suggesting that participants 
were more focused on current issues than upcoming prob-
lems, and that it was easier for them to accept physical 
limitations associated with their condition than social or 
psychological implications. A similar situation has previ-
ously supported this idea in individuals with ALS [51]. 
These results are similar to previous frequency analysis 
in NMD [24].
The analysis by visit displayed similar percentages for 
each domain, which is consistent with our findings for global 
analysis. Taking into account the number of quotes per visit, 
baseline interviews included more comments. This observa-
tion suggests that participants were inclined to provide more 
information at the beginning of the study as it was their first 
visit/interview. Perhaps this was also due to positive expec-
tations of the trial [47]. Normalized percentages per visit 
reported similar results, revealing that participants provided 
comparable information in each visit. Finally, results for data 
transformation analysis by participant resulted in a similar 
trend to the global analysis findings.
As previously stated, RYR1-RM are slowly progres-
sive diseases, which makes it necessary to capture disease 
progression when considering effects of treatments and 
HRQoL. This issue was captured though the identification of 
the domain and subdomain of post-intervention and disease 
progression. Both concepts were analyzed in qualitative and 
data transformation analyses.
Three domains from Neuro-QoL showed some evidence 
of a difference between the NAC and placebo groups, 
fatigue, anxiety, and stigma. The p values for these domains 
ranged between 0.014 and 0.034, which do not reflect strong 
evidence of a difference given that 20 tests were performed. 
The sample size was small given the rare nature of the dis-
ease, and therefore the statistical power to detect differences 
was also small. Likewise, although there was a trend on the 
subjective self-assessment, suggesting a potential positive 
effect of NAC on participants with RYR1-RM, our sample 
Table 4  Results from t-test for PROMIS and Neuro-QoL instruments (in order of lowest to highest p value)
a Change = month 12 T-score minus month 6 T-score
b p values are unadjusted for multiple comparisons







 changea in NAC 
group









p  valueb 
for zero 
difference
Neuro-QoL-anxiety 12 12  − 5.82  − 0.11  − 5.71  − 10.16  − 1.26 0.014
Neuro-QoL-stigma 12 12  − 5.15 0.03  − 5.17  − 9.81  − 0.53 0.030
Neuro-QoL-fatigue 12 12  − 6.16 0.14  − 6.30  − 12.09  − 0.51 0.034
PROMIS-peer relations 3 5  − 4.75 3.81  − 8.57  − 19.39 2.26 0.101
PROMIS-pain 12 11  − 7.54  − 1.65  − 5.90  − 13.50 1.70 0.116
Neuro-QoL-participate 
in SRA
9 6 3.43 0.28 3.15  − 2.04 8.34 0.148
Neuro-QoL-mobility 9 6 2.85  − 0.37 3.21  − 1.36 7.78 0.153
PROMIS-fatigue 12 11  − 7.79  − 2.58  − 5.21  − 12.94 2.51 0.168
PROMIS-mobility 12 11 1.92  − 0.80 2.72  − 1.31 6.74 0.175
PROMIS-social 9 6 6.35 1.32 5.03  − 4.19 14.25 0.185
Neuro-QoL-upper 
extremity
9 6 2.29  − 0.53 2.82  − 2.57 8.21 0.200
PROMIS-upper extremity 12 11 2.86 1.10 1.77  − 1.97 5.50 0.326
Neuro-QoL-social rela-
tions
3 2 6.76 1.81 4.95  − 11.48 21.38 0.408
Neuro-QoL-applied 
cognition
3 2 3.76  − 2.96 6.72  − 16.17 29.62 0.419
Neuro-QoL-Pain 3 6  − 3.50  − 0.79  − 2.72  − 12.48 7.05 0.532
Neuro-QoL-depression 12 8  − 2.62  − 0.63  − 1.99  − 8.57 4.60 0.534
PROMIS-anxiety 12 12  − 3.93  − 2.79  − 1.14  − 6.11 3.83 0.639
Neuro-QoL-anger 3 6  − 4.74  − 3.30  − 1.44  − 14.76 11.87 0.805
PROMIS-anger 12 11  − 3.62  − 3.12  − 0.50  − 6.93 5.94 0.874
PROMIS-depression 12 12  − 3.66  − 3.43  − 0.23  − 5.03 4.58 0.923
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size may be too small to produce strong evidence of a causal 
relationship between subjective self-assessment and NAC 
treatment. Thus, there was no clear evidence that any of the 
three tools captured positive changes as a result of NAC 
treatment on quantitative analysis. Interestingly, the results 
of our analyses of both subjective quantitative and qualita-
tive/transformed data were similar to our findings from our 
primary endpoints in that NAC did not significantly improve 
any endpoints [9].
As mentioned, the main limitation in this study (for the 
transformed and quantitative analyses) was the sample size, 
which was small. Another major limitation was that all 
enrolled participants were ambulatory due to 6MWT being a 
primary endpoint, which meant that only mild-to-moderately 
affected individuals were enrolled.
Conclusion
Our qualitative analysis provides salient information on 
the major concerns/issues participants with RYR1-RM face 
and how they describe those concerns/issues affecting their 
HRQoL. We present a comprehensive characterization of 
HRQoL, in mild-to-moderately affected individuals, based 
on a symptom/patient-centered approach. These findings, 
especially the importance of social impacts, the develop-
ment of several coping strategies, both physical and psy-
chological, and the identification of fatigue and weakness 
as key symptoms, will inform future studies in this rare 
disease. However, at this dose, there was no clear evidence 
that NAC improved PRO scores for PROMIS or Neuro-QoL. 
Furthermore, although treatment benefits were mentioned 
by more (blinded) participants on NAC than placebo dur-
ing qualitative interviews, once the qualitative data were 
transformed and quantified, evidence of a difference was 
not conclusive. Interestingly, these findings were similar to 
our primary endpoints and PRO results, in which 6MWT 
approached a clinically meaningful change, but no clear 
difference post-NAC treatment was identified in 6MWT or 
oxidative stress levels. Given the similar findings across our 
multiple methods and endpoints, the introduction of MMR, 
namely qualitative interviews and their data transformation, 
may be a valuable, complementary approach to clinical tri-
als. Although this type of analysis requires a distinct skill set 
from many trial endpoints, MMR may be especially useful to 
incorporate in clinical studies in order to address and follow 
the FDA’s guidance and prioritization on the inclusion of 
affected individuals’ perspectives in clinical trials.
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